Unequal access to cancer care can no longer be tolerated

September 26, 2011 in Cancer

Cancer is one of the leading causes of death and morbidity worldwide, and its economic burden grows year by year. In 2008, the worldwide cost of cancer due to premature death and disability, excluding direct medical costs, was estimated to be US$895 billion.

An expert report from The Commission (Lancet Oncol 2011; 12: 933-80.), a group of some of the world's leading cancer specialists, from patient advocates to economists and healthcare professionals, published today (Monday 26 September), tries to tackle the difficult problem of how to deliver affordable high quality and equitable in . Presenting the report to the 2011 European Multidisciplinary Cancer Congress [2], Professor Richard Sullivan from the King's Health Partners Integrated Cancer Centre (a collaboration between King's College London and its partner NHS Foundation Trusts – Guy's and St Thomas' and King's College Hospital, London, UK) said that ageing populations and the increasing complexity and cost of new cancer treatments meant that this issue needed urgent solutions.

"The Economist Intelligence Unit estimates the costs associated with new cancer cases alone in 2009 to be at least $286 billion. make up more than half the , and productivity losses account for nearly a quarter. By 2030, there will be an estimated 22 million new patients with cancer per year worldwide," he said. "The global challenge to countries is how to deliver reasonably priced cancer care to all citizens – i.e. make cancer care affordable to individuals and society."

At a time when the global cancer burden is shifting to low and middle-income countries, it may seem strange to concentrate on wealthier nations, the authors say, but the unique health and disease trajectory involved in those countries through the added burden of significant acute, infectious and chronic disease necessitates a separate approach. The massive increase in expenditure on cancer care in high income countries over the last two decades is due to many factors: over-utilisation (for example, tests which are useful in one setting and not in another), high-cost innovation, disincentivisation driven by reimbursement rules and defensive medical practice – more tests and treatment to counter litigation-driven culture – consumer-driven over-demand, and futile over-treatment at the end of life.

The authors identify a whole range of immediate and medium term measures that need to be introduced to reduce the current cost base of delivering cancer care and manage the future cost curves of particularly expensive interventions such as cancer medicines. Radical action is needed to simplify and integrate patient treatment pathways, new models of care with lower cost bases need to be implemented and a whole new approach to expensive interventions – from mandatory cost-effectiveness analysis, to the prohibition of off-label use and new economic models for reimbursement and incentivisation – must be driven through healthcare systems.

Educating the public, patients and policymakers about the key issues in delivering affordable cancer care is also essential, say the authors. "Making individual patients more sensitive to the costs of care is necessary for an informed public debate around this critical issue," said Professor Sullivan.

A radical shift in cancer policy is required, the report's authors say. Political tolerance of unfairness in access to affordable cancer treatment is unacceptable. The cancer community needs to take responsibility and not accept a sub-standard evidence base and an ethos of very small benefit at whatever cost; rather there should be fair prices and real value from new technologies.

"We are at a crossroads for affordable cancer care, where our choices – or refusal to make choices – will affect the lives of millions of people. Do we bury our heads in the sand, keep our fingers crossed, and hope that it turns out fine, or do we have difficult debates and make hard choices within a socially responsible, cost-effective, and sustainable framework? The consensus from all those involved is that policy makers, politicians, patients, and health care professionals need to address this issue now," Professor Sullivan said.

"We believe that value and affordable cancer care can be introduced into the cancer policy lexicon without detracting from quality, and that the management tools, evidence, and methods are available to affect this transformation across all developed countries," he concluded.

ECCO President Professor Michael Baumann said: "It is of the utmost importance that oncology professionals promote evidence-based discussion of the economics of cancer care. All health systems face budget limitations, while at the same time the cancer burden and expenditures are increasing steeply. Every cancer patient, now and in the future, must have fair access to quality care and to innovation. This can only be safeguarded by transparent and evidence-based analysis and policy development. This initiative by Lancet Oncology is a very important step in this direction."

Provided by ECCO-the European CanCer Organisation

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Small increase in cancer risk following CT scans in childhood and adolescence

Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.

Cancer created 47 minutes ago | popularity not rated yet | comments 0

Cancer survivors need more support to stop smoking and drinking

Cancer survivors are no more likely to stop smoking, cut down on alcohol, or exercise more often than the general population, according to new research published in the British Journal of Cancer today (Wednesday)

Cancer created 2 hours ago | popularity not rated yet | comments 0

Beta-blockers may boost chemo effect in childhood cancer

Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Jo ...

Cancer created 2 hours ago | popularity not rated yet | comments 0

Japan hospital tests powerful breast cancer therapy

A Japanese cancer specialist said Wednesday she has started the world's first clinical trial of a powerful, non-surgical, short-term radiation therapy for breast cancer.

Cancer created 2 hours ago | popularity not rated yet | comments 0

Small cancer risk following CT scans in childhood and adolescence confirmed

The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...

Cancer created 15 hours ago | popularity not rated yet | comments 0


Addiction to unhealthy foods could help explain the global obesity epidemic

Research presented today shows that high-fructose corn syrup can cause behavioural reactions in rats similar to those produced by drugs of abuse such as cocaine. These results, presented by addiction expert Francesco Leri, ...

Study shows low rate of late lumen loss with bioresorbable DESolve device

The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...

Study finds COPD is over-diagnosed among uninsured patients

More than 40 percent of patients being treated for COPD at a federally funded clinic did not have the disease, researchers found after evaluating the patients with spirometry, the diagnostic "gold standard" for chronic obstructive ...

Registry questions superiority of bivalirudin over heparin

Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...

New blood-thinner measures may cut medication errors

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...

Indian medics reconstruct baby's swollen head

Indian doctors said Wednesday they have successfully carried out a first round of reconstructive surgery on the skull of a baby suffering from a rare disorder that caused her head to nearly double in size.